‹ Back

AI/ML Trends in MedTech: Navigating the Surge in AI/ML-Enabled Device Approvals

May 13, 2026 | CAHIR Solutions 

 

 

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into medical devices is a present-day reality that is reshaping patient care, diagnostics, and clinical workflows. Our analysis of recent market data reveals a rapid acceleration in the adoption of these technologies, signaling a new frontier for medtech stakeholders worldwide.

 

The "Hockey Stick" Growth

The data tells a compelling story of exponential growth. While the early 2000s saw only a trickle of AI/ML-enabled device approvals, the landscape shifted dramatically around 2016. From just 18 approvals in 2016, the volume surged to 226 in 2023, reaching a peak of 331 in 2025. This is a 32% increase in just two years.  As of the FDA’s latest data update in March, the device center had authorized more 1,400 AI devices since 1995.

 

This rapid ascent, as shown in the chart "Growth of AI/ML-Enabled Medical Device Approvals (2015-2025)", reflects not only technological breakthroughs but also a maturing regulatory environment that is increasingly adept at evaluating software-as-a-medical-device (SaMD).

 

Growth of AI/ML-Enabled Medical Device Approvals (1995-2025)

 

Radiology: The Vanguard of AI Integration

Radiology remains the dominant field for AI/ML applications, accounting for approximately 76.5% (1,094 devices) of all approvals in our dataset. The ability of AI to enhance image interpretation, automate measurements, and prioritize urgent cases has made it indispensable tool for radiologists.

 

 

However, we are also seeing significant inroads in other specialties:

Cardiovascular: 136 devices (e.g., arrhythmia detection and cardiac imaging).

Neurology: 65 devices (e.g., stroke diagnosis and brain mapping).

Anesthesiology & Gastroenterology: Emerging sectors with 26 and 24 approvals respectively.

 

A Diverse and Competitive Market

The market is characterized by both established healthcare giants and agile AI-first innovators. Siemens Medical Solutions USA, Inc. leads with 70 approved devices, followed by Canon Medical Systems (38) and Aidoc Medical, Ltd. (31).  Note that when all Philips subsidiaries are combined, they have a total of 38 FDA-approved devices, while GE’s subsidiaries collectively account for 98 FDA-approved AI/ML devices.

 

With hundreds of unique companies represented in the data, it is clear that the barrier to entry is lowering for specialized AI firms, fostering a vibrant ecosystem of innovation that benefits patients and providers alike.

 

 

Why This Matters for Stakeholders

For Clinicians: AI is becoming a standard "co-pilot," offering decision support that can reduce burnout and improve diagnostic accuracy. The shift from "experimental" to "essential" is happening now.

 

For Regulators: The focus is shifting toward Predetermined Change Control Plans (PCCPs), allowing devices to evolve safely post-market without requiring a new submission for every minor algorithmic update.

 

For Investors: The medtech sector is ripe with opportunities, particularly in underserved specialties where AI has yet to make its mark. The "Radiology blueprint" is now being applied to pathology, oncology, and beyond.

 

For Manufacturers: Speed-to-market and regulatory strategy are more critical than ever. Understanding the competitive landscape—where Siemens and GE dominate versus where startups like Aidoc are carving out niches—is key to success.

 

The surge in AI/ML-enabled devices is more than just a trend; it’s a fundamental shift in the medical device industry.

 

What does this mean for you?

Whether you're a clinician looking for a digital "co-pilot" to reduce burnout or an investor seeking the next frontier, the AI MedTech landscape is ripe with opportunity.

 

At Cahir Solutions, we are committed to helping our medtech partners navigate this complex regulatory and technological landscape with hands-on and evidence-based full life-cycle support activities (The Cahir Pathway) proven to successfully launch medical devices with efficiency and precision in the U.S. market. 

 

Our MD Practice Lead brings over a decade of experience navigating the U.S. healthcare regulatory landscape, with deep expertise in product development, payer coding and reimbursement. This is complemented by a strong technical foundation of a biomedical engineer and Pharm D team, specializing in De Novo and 510(k) study design, biocompatibility, patient care safety and quality, risks management, and regulatory submissions.  

#MedTech #AI #HealthTech #Innovation #CahirSolutions #MedicalDevices #Radiology #FutureOfHealthcare

 

Summary of Dataset Parameters and Characteristics:

Cahir Solutions downloaded the FDA’s list of AI/ML-enabled medical devices on May 12, 2026. The FDA last updated the database on March 06, 2026. The FDA compiled the list using product codes and device summaries. The list is not exhaustive.

• AI/ML-Enabled Medical Device Approvals (1995-2025)

• Data obtained directly from FDA webpage on 5.2026

• Additonal information provided with the dataset: the list is not a comprehensive resource of AI-enabled medical devices. Instead, the list includes AI-enabled medical devices that were identified primarily based on the use of AI-related terms in the summary descriptions of their marketing authorization document and/or the device’s classification.